What is ANVS stock price today?

ANVS (Annovis Bio Inc) stock is trading at $1.73 as of the latest market data. Stock prices update in real-time during market hours (9:30 AM - 4:00 PM ET).

Is ANVS stock going up or down today?

ANVS stock price movements are influenced by market conditions, news, earnings reports, and investor sentiment. Check our live dashboard for real-time price changes and technical indicators.

Should I buy ANVS stock now?

The decision to buy ANVS depends on your investment strategy, risk tolerance, and financial goals. Our AI analysis evaluates fundamentals, valuation metrics, growth prospects, and market conditions to help inform your decision.

Is ANVS a buy, hold, or sell right now?

Our AI-powered analysis provides buy/hold/sell recommendations for ANVS based on multiple factors including valuation, growth metrics, technical indicators, and analyst consensus. Visit our dashboard for the latest recommendation.

Is ANVS stock overvalued or undervalued?

Use our DCF valuation calculator to determine if ANVS is overvalued or undervalued based on fundamental analysis and future cash flow projections.

What is ANVS's P/E ratio?

P/E ratio data for ANVS will be available after the company reports earnings. Visit our dashboard for the latest financial metrics.

What is ANVS's market cap?

ANVS (Annovis Bio Inc) has a market capitalization of $0.05 billion, making it a small-cap stock.

What is ANVS's price to book ratio?

ANVS trades at a price-to-book (P/B) ratio of 2.88, which compares the stock price to the company's book value per share. A P/B below 1.0 may indicate undervaluation, while above 3.0 may suggest premium pricing.

Does ANVS pay dividends?

ANVS does not currently pay dividends. Many growth companies reinvest profits into the business rather than paying dividends.

What is ANVS's dividend yield?

ANVS does not currently pay dividends or dividend data is not available. Check our dashboard for the latest information.

Is ANVS stock a good long-term investment?

ANVS's long-term investment potential depends on sustainable competitive advantages, revenue growth, profitability, management quality, and industry dynamics. Our AI analysis evaluates these factors to assess long-term prospects.

What is ANVS's revenue growth rate?

Revenue growth data for ANVS is available on our dashboard with detailed financial statement analysis.

Profitability metrics for ANVS are available on our dashboard with complete income statement analysis.

What are the risks of investing in ANVS?

Key risks for ANVS include market volatility, competitive pressures, regulatory changes, economic conditions, execution risks, and company-specific factors. Our AI analysis identifies material risks and their potential impact on valuation.

How does ANVS compare to its competitors?

Compare ANVS to industry peers on our dashboard using metrics like P/E ratio, revenue growth, profit margins, market share, and valuation multiples. Competitive analysis helps contextualize ANVS's performance and positioning.

What is ANVS's stock price target for 2026?

Our AI model provides price targets for ANVS based on fundamental analysis: Bull case $2.24 (+30%), Base case $1.98 (+15%), Bear case $1.55 (-10%). Visit our prediction page for detailed forecasts.

What do analysts say about ANVS?

Wall Street analysts provide ratings (buy/hold/sell) and price targets for ANVS. Our dashboard aggregates analyst consensus, target prices, and recent upgrades/downgrades to help you understand professional sentiment.

When is ANVS's next earnings report?

ANVS reports earnings quarterly. Check our dashboard for the upcoming earnings date, analyst estimates for revenue and EPS, and historical earnings performance. Earnings reports often drive significant stock price movements.

ANVS - Annovis Bio Inc

NYSE * Health Care * Biotechnology

$1.73

$-0.01 (-0.29%)

About Annovis Bio Inc

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's lead product candidate is Buntanetap, which is in phase 2/3 to treat alzheimer's disease, as well as in phase 3 to treat parkinson's disease; and is in phase 2 clinical trial to treat lewy body dementia. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer's disease and dementia. Annovis Bio, Inc. was incorporated in 2008 and is headquartered in Malvern, Pennsylvania.

ANVS Key Statistics

Market Cap

$50.64M

P/B Ratio

2.88

EPS

$-1.40

Employees

How ANVS Compares to Peers

ANVS is the smallest among peers, which may offer higher growth potential

P/E Rank

N/A

of 5

Margin Rank

N/A

of 5

Growth Rank

N/A

of 5

Size Rank

of 6

Company	Market Cap	P/E	Growth	Margin	Compare
ANVS(This stock)	$50.64M	N/A	0%	0.0%	-
AMGNAmgen Inc	$189.19B	24.7	0%	0.2%	vs AMGN
GILDGilead Sciences	$174.33B	20.7	0%	0.3%	vs GILD
VRTXVertex Pharmaceuticals	$113.01B	29.0	0%	0.3%	vs VRTX
REGNRegeneron Pharmaceuticals	$79.87B	18.2	0%	0.3%	vs REGN
BIIBBiogen Inc	$26.26B	20.4	-0%	0.1%	vs BIIB

Annovis Bio Inc Company Information

Headquarters: Pennsylvania; U.S.A
Website: www.annovisbio.com
Sector: Health Care
Industry: Biotechnology

Data Updated: April 15, 2026 at 11:44 PM EDT

Ready to invest in ANVS?

Commission-free trading available. Affiliate links.

ANVS Lician Score

5% confidence

4.0/10

Neutral

ANVS has a Lician Score of 4/10 (Average). Areas of concern: Growth.

value

5.0

growth

2.0

quality

5.0

momentum

5.0

safety

5.0

The Lician Score is a comprehensive 1-10 rating that evaluates ANVSacross five key dimensions: Value (valuation relative to sector),Growth (revenue and earnings trajectory),Quality (profitability and balance sheet strength),Momentum (price trends and analyst sentiment), andSafety (volatility and risk metrics).

ANVS Financial Snowflake

5-axis analysis across key investment dimensions

4.4/10

Neutral

5.0

Value

Valuation vs. sector peers

2.0

Growth

Revenue & earnings trajectory

5.0

Quality

Profitability & moat strength

5.0

Momentum

Price trends & analyst sentiment

5.0

Safety

Financial stability & risk

Upcoming Events for ANVS

Dashboard

Enter a ticker to analyze